We recently published a list of Jim Cramer’s Latest Stock Moves: Top 10 Calls. In this article, we are going to take a look ...

The organizations will be honored, beginning at 8:05 am, during the Friday Plenary Keynote session of the Bio-IT World ...

Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...

Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...

What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many ...

In the current session, Regeneron Pharmaceuticals Inc. REGN is trading at $672.39, after a 0.89% decrease. Over the past month, the stock decreased by 0.97%, and in the past year, by 30.36%. With ...

One Triangle student developed a potential treatment for a rare genetic disorder that primarily impacts the Lumbee tribe.